NCT03159455View on ClinicalTrials.gov

This Study Tests BI 1467335 in Healthy Japanese and Caucasian Men. The Study Tests How Different Doses of BI 1467335 Are Taken up in the Body and How Well They Are Tolerated

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

June 7, 2017

Primary Completion Date

December 16, 2017

Study Completion Date

December 16, 2017

Conditions
Healthy
Interventions
DRUG

BI 1467335

Duration - 28 days

DRUG

Placebo

Duration - 28 days

Trial Locations (2)

812-0025

Souseikai Hakata Clinic, Fukuoka, Fukuoka

130-0004

SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT03159455 - This Study Tests BI 1467335 in Healthy Japanese and Caucasian Men. The Study Tests How Different Doses of BI 1467335 Are Taken up in the Body and How Well They Are Tolerated | Biotech Hunter | Biotech Hunter